2.13 0.06 (2.9%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 3.56 | 1-year : | 4.3 |
Resists | First : | 3.05 | Second : | 3.69 |
Pivot price | 2.3 | |||
Supports | First : | 2.01 | Second : | 1.68 |
MAs | MA(5) : | 2.14 | MA(20) : | 2.32 |
MA(100) : | 3.49 | MA(250) : | 14.98 | |
MACD | MACD : | -0.3 | Signal : | -0.3 |
%K %D | K(14,3) : | 6.6 | D(3) : | 9.7 |
RSI | RSI(14): 39.2 | |||
52-week | High : | 86.87 | Low : | 2.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BBLG ] has closed above bottom band by 21.8%. Bollinger Bands are 66.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.26 - 2.27 | 2.27 - 2.29 |
Low: | 1.99 - 2.01 | 2.01 - 2.02 |
Close: | 2.11 - 2.13 | 2.13 - 2.15 |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Thu, 28 Mar 2024
Bone Biologics Co. (NASDAQ:BBLG) Short Interest Down 75.1% in March - Defense World
Tue, 26 Mar 2024
Bone Biologics (OTC:BBLG) Stock Price Down 1.3% - Defense World
Thu, 14 Mar 2024
Should You Buy Bone Biologics Corp (BBLG) Stock After it Is Up 2.99% in a Week? - InvestorsObserver
Wed, 06 Mar 2024
Bone Biologics Announces Closing of $2.0 Million Public Offering - OrthoSpineNews
Mon, 04 Mar 2024
Bone Biologics rises 5% on $2M equity offering (NASDAQ:BBLG) - Seeking Alpha
Fri, 01 Mar 2024
Bone Biologics Reports Progress With NB1 Clinical Program - OrthoSpineNews
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 1 (M) |
Shares Float | 0 (M) |
Held by Insiders | 8.1 (%) |
Held by Institutions | 1.2 (%) |
Shares Short | 125 (K) |
Shares Short P.Month | 10 (K) |
EPS | -34.01 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 5.44 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -96.4 % |
Return on Equity (ttm) | -202.2 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -10 (M) |
Levered Free Cash Flow | -7 (M) |
PE Ratio | -0.07 |
PEG Ratio | 0 |
Price to Book value | 0.39 |
Price to Sales | 0 |
Price to Cash Flow | -0.2 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |